Ocugen Inc
OCGN1.010USD
+0.016+1.64%
시장 운영 시간 （ET）시세는 15분 지연됩니다
294.92M시가총액
손실P/E TTM
자세한 내용은 Ocugen Inc 회사
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
회사 정보
종목 코드 OCGN
회사 이름Ocugen Inc
상장일Dec 03, 2014
CEODr. Shankar Musunuri, Ph.D.
직원 수95
유형Ordinary Share
회계 연도 종료Dec 03
주소11 Great Valley Parkway
도시MALVERN
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호19355
전화14843284701
웹사이트https://ocugen.com/
종목 코드 OCGN
상장일Dec 03, 2014
CEODr. Shankar Musunuri, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+0.01%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+250.87%
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
75.00K
+50.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+0.01%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+250.87%
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
75.00K
+50.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
수익 분석
FY2025Q1
FY2024
FY2023
FY2021
FY2020
데이터 없음
지역별USD
이름
수익
비율
United States
1.48M
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 17
마지막 업데이트: Sat, May 17
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
6.24%
The Vanguard Group, Inc.
5.71%
Geode Capital Management, L.L.C.
2.36%
State Street Global Advisors (US)
2.03%
GMT Capital Corp.
1.42%
Other
82.24%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
6.24%
The Vanguard Group, Inc.
5.71%
Geode Capital Management, L.L.C.
2.36%
State Street Global Advisors (US)
2.03%
GMT Capital Corp.
1.42%
Other
82.24%
주주 유형
주주
비율
Investment Advisor
15.79%
Investment Advisor/Hedge Fund
6.52%
Hedge Fund
3.35%
Individual Investor
1.21%
Research Firm
0.74%
Corporation
0.39%
Bank and Trust
0.17%
Pension Fund
0.02%
Other
71.80%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
267
82.38M
28.21%
-9.38M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
2023Q3
314
37.28M
14.69%
-34.75M
2023Q2
332
53.23M
20.91%
-28.29M
2023Q1
336
68.93M
30.49%
-36.35M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
18.22M
6.24%
-377.91K
-2.03%
Mar 31, 2025
The Vanguard Group, Inc.
16.68M
5.71%
+64.02K
+0.39%
Mar 31, 2025
Geode Capital Management, L.L.C.
6.89M
2.36%
+300.41K
+4.56%
Mar 31, 2025
State Street Global Advisors (US)
5.93M
2.03%
+65.93K
+1.12%
Mar 31, 2025
GMT Capital Corp.
4.15M
1.42%
+1.70M
+69.20%
Mar 31, 2025
UBS Financial Services, Inc.
4.15M
1.42%
+3.42M
+469.31%
Mar 31, 2025
Renaissance Technologies LLC
3.46M
1.18%
+1.37M
+65.70%
Mar 31, 2025
Northern Trust Investments, Inc.
2.30M
0.79%
-103.69K
-4.31%
Mar 31, 2025
GSA Capital Partners LLP
1.64M
0.56%
+492.30K
+42.97%
Mar 31, 2025
Musunuri (Shankar Ph.D)
1.34M
0.46%
+607.32K
+82.50%
Apr 14, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Micro-Cap ETF
0.01%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
더 보기
Invesco NASDAQ Future Gen 200 ETF
비율0.52%
iShares Micro-Cap ETF
비율0.01%
Pacer WealthShield ETF
비율0%
iShares Russell 2000 ETF
비율0%
ProShares UltraPro Russell2000
비율0%
ProShares Hedge Replication ETF
비율0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
Global X Russell 2000 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
